Key facts
- Adcytherix’s last known valuation is $213.3M (Jul 2025).
- It has raised $160.8M across 2 recorded rounds; the latest was Early Stage VC (Series A) ($126.3M) in Jul 2025.
- Notable investors include Bpifrance, RA Capital Management, Kinled Holding, European Investment Bank, Kurma Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Adcytherix
Funding rounds
2 roundsAbout Adcytherix
Developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation. The company offers new classes of payload mechanisms, advanced ADC design, and optimization beyond standard tubulin/topoisomerase inhibitors, enabling oncologists and cancer patients to benefit from effective targeted treatments with low side effects.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Marseille, France
- Founded
- 2024
- Employees
- 11
- Website
- adcytherix.com/
- Ownership
- Privately Held (backing)
Adcytherix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adcytherix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adcytherix in its N-PORT filings yet. We sweep new filings monthly.